« Back
Home /
Lenalidomide

Lenalidomide

Item no.	HY-A0003-500mg
Manufacturer	MedChem Express
CASRN	191732-72-6
Amount	500 mg
Quantity options	100 mg 10 mM/1 mL 1 g 500 mg 5 g
Category	Oncology Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Neural Development Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer Lymphatic System Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.\|[2]Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36.\|[3]Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35.\|[4]Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82.\|[5]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.\|[6]Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1.\|[7]Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3(7):e941742. ACS Omega. 2024 Dec 3;9(50):49739-49748. ACS Pharmacol Transl Sci. 2021 Feb 26;4(2):941-952. Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254. Acta Pharmacol Sin. 2025 Aug;46(8):2296-2309. Am J Pathol. 2015 Jun;185(6):1783-94. Biochim Biophys Acta Mol Basis Dis. 2022 Oct 1;1868(10):166472. Bioengineering (Basel). 2025 Oct 19;12(10):1121. bioRxiv. 2024 June 12. bioRxiv. 2024 October 19. bioRxiv. April. Cancer Cell. 2022 Nov 14;40(11):1294-1305.e4. Cancer Res. 2025 Jan 2;85(1):101-117. Cancer Sci. 2019 Dec;110(12):3802-3810. Cancers (Basel). 2024 Mar 28, 16(7), 1319. Cell Rep Med. 2024 Mar 19;5(3):101472. Cell Rep Med. 2025 Apr 2:102053. Cell Rep Methods. 2023 Oct 23;3(10):100599. Cell Rep. 2024 May 8;43(5):114211. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Cell. 2018 Sep 20;175(1):171-185.e25. Chemrxiv. 2025 Nov 17. Clin Chim Acta. 2024 Jan 15:553:117707. Elife. 2018 Aug 1;7:e38430. Eur J Pharmacol. 2025 Dec 5:1008:178303. Exp Cell Res. 2020 Aug 1;393(1):112054. Faculty of Science, Masaryk University. Department of Experimental Biology.2014. Food Chem Toxicol. 2019 Mar:125:392-402. Free Radic Biol Med. 2023 Jul:203:86-101. Front Cell Infect Microbiol. 2022 Jul 28;12:954814. Harvard Medical School LINCS LIBRARY Harvard University. 2025. Inflammation. 2019 Feb;42(1):221-234. Int Immunopharmacol. 2025 May 14:158:114831. Int J Mol Sci. 2023 Sep 14;24(18):14097. iScience. 2022 Jul 19;25(8):104781. J Transl Med. 2024 Dec 3;22(1):1095. Leukemia. 2025 Mar;39(3):720-733. Microbiome. 2025 Feb 28;13(1):56. Mol Ther Oncol. 2025 Feb 20;33(1):200952. Nat Cancer. 2022 May;3(5):595-613. Nat Chem Biol. 2021 Jun;17(6):711-717. Nat Commun. 2017 May 22;8:15398. Nat Commun. 2025 Nov 6;16(1):9805. Nat Commun. 2025 Sep 1;16(1):8155. Nature. 2024 Sep;633(8030):670-677. Neoplasia. 2025 Oct 27:70:101243. Oncol Rep. 2018 Jun;39(6):2873-2880. Oxid Med Cell Longev. 2021 Dec 29:2021:8302831. Patent. US20170360780A1. Patent. US20180263995A1. Patent. US20210379039A1. Patent. US20220332776A1. Patent. US20240261246A1. Universidad de Navarra. 2024 Feb 28. University of Washington. The Columbian College of Arts and Sciences. August 31, 2021. Cell Commun Signal. 2025 May 7;23(1):216. Food Chem Toxicol. 2019 Mar:125:392-402.
Smiles	O=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CC-5013
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Apoptosis; Ligands for E3 Ligase; Molecular Glues
Manufacturer - HS Code	H361, H373
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	259.26
Product Description	Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; PROTAC
Clinical information	Launched
Isoform	Cereblon
UNSPSC Code	12352005
Precautionary	H361, H373

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.